107 related articles for article (PubMed ID: 12087588)
1. Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.
Lockridge L; Papac RJ; Perazella MA
Am J Kidney Dis; 2002 Jul; 40(1):E2. PubMed ID: 12087588
[TBL] [Abstract][Full Text] [Related]
2. Nephrotic syndrome and renal failure in a patient with metastatic breast cancer.
Yoshizawa H; Akimoto T; Nishino K; Inoue M; Ito C; Takeda S; Kotoda A; Tamba K; Yumura W; Muto S; Ueda Y; Kusano E
Clin Exp Nephrol; 2011 Aug; 15(4):567-71. PubMed ID: 21416249
[TBL] [Abstract][Full Text] [Related]
3. Nephrotic syndrome after treatment with pamidronate.
Markowitz GS; Fine PL; D'agati VD
Am J Kidney Dis; 2002 May; 39(5):1118-22. PubMed ID: 11979358
[No Abstract] [Full Text] [Related]
4. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity.
Banerjee D; Asif A; Striker L; Preston RA; Bourgoignie JJ; Roth D
Am J Kidney Dis; 2003 May; 41(5):E18. PubMed ID: 12778436
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
6. Safety of pamidronate in patients with renal failure and hypercalcemia.
Machado CE; Flombaum CD
Clin Nephrol; 1996 Mar; 45(3):175-9. PubMed ID: 8706358
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
8. [Langerhans cell granulomatosis of the lung (morphological studies of lung biopsy specimens from patient with histiocytosis X].
Tiszlavicz L; Krenács L; Kovács K; Csanádi J; Szalontai K
Orv Hetil; 1997 Jan; 138(4):215-8. PubMed ID: 9072755
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Langerhans cell histiocytosis with pamidronate.
Farran RP; Zaretski E; Egeler RM
J Pediatr Hematol Oncol; 2001 Jan; 23(1):54-6. PubMed ID: 11196272
[TBL] [Abstract][Full Text] [Related]
10. More on pamidronate in Langerhans'-cell histiocytosis.
Egeler RM
N Engl J Med; 2001 Nov; 345(20):1502-3. PubMed ID: 11794212
[No Abstract] [Full Text] [Related]
11. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
12. More on pamidronate in Langerhans'-cell histiocytosis.
Brown RE
N Engl J Med; 2001 Nov; 345(20):1503. PubMed ID: 11794213
[No Abstract] [Full Text] [Related]
13. Nephrotic syndrome induced by pamidronate.
ten Dam MA; Hilbrands LB; Wetzels JF
Med Oncol; 2011 Dec; 28(4):1196-200. PubMed ID: 20865462
[TBL] [Abstract][Full Text] [Related]
14. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.
Migliorati CA; Schubert MM; Peterson DE; Seneda LM
Cancer; 2005 Jul; 104(1):83-93. PubMed ID: 15929121
[TBL] [Abstract][Full Text] [Related]
16. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients.
Amital H; Applbaum YH; Aamar S; Daniel N; Rubinow A
Rheumatology (Oxford); 2004 May; 43(5):658-61. PubMed ID: 14983108
[TBL] [Abstract][Full Text] [Related]
17. The development of cast nephropathy in multiple myeloma.
Iggo N; Winearls CG; Davies DR
QJM; 1997 Nov; 90(11):653-6. PubMed ID: 9474345
[No Abstract] [Full Text] [Related]
18. Pamidronate in the treatment of childhood SAPHO syndrome.
Kerrison C; Davidson JE; Cleary AG; Beresford MW
Rheumatology (Oxford); 2004 Oct; 43(10):1246-51. PubMed ID: 15238641
[TBL] [Abstract][Full Text] [Related]
19. Podocyte injury associated glomerulopathies induced by pamidronate.
Barri YM; Munshi NC; Sukumalchantra S; Abulezz SR; Bonsib SM; Wallach J; Walker PD
Kidney Int; 2004 Feb; 65(2):634-41. PubMed ID: 14717935
[TBL] [Abstract][Full Text] [Related]
20. Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis.
Arzoo K; Sadeghi S; Pullarkat V
N Engl J Med; 2001 Jul; 345(3):225. PubMed ID: 11463032
[No Abstract] [Full Text] [Related]
[Next] [New Search]
